In the Claims:

Cancel claims 1-19, without prejudice.

The following claims 20 and 22-26 are amended, as indicated in the attached marked up version:

20. (1st Time Amended) A pharmaceutical composition comprising a therapeutically effective amount of a 2-thienyl imidazolo[4,5]pyridine having the formula:



wherein,

n is from 1 to 3; and

R is selected from the group consisting of hydrogen, alkyl having from 1 to 7 carbon atoms, chloro, bromo, fluoro, oxychloro, hydroxy, sulfhydryl, and alkoxy having the formula $-O(CH_2)_yCH_3$ wherein y is from 0 to 6.

22. (1st Time Amended) A pharmaceutical composition according to Claim 28 wherein said pharmaceutical addition salt is selected from the group consisting of chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and mixtures thereof.

23. (1st Time Amended) A pharmaceutical composition according to Claim 22 comprising from about 150 mg to about 5000 mg of said 2-thienyl imidazolo[4,5]pyridine.

24. (1st Time Amended) A pharmaceutical composition according to Claim 23 which further comprises a pharmaceutical carrier.

25. (1st Time Amended) A pharmaceutical composition according to Claim 24 which is in a solid form wherein said pharmaceutical carrier is selected from the group consisting of lactose, sucrose, gelatin, cyclodextrin, substituted cyclodextrin, and agar.

26. (1st Time Amended) A pharmaceutical composition according to Claim 25 which is in a liquid form wherein said liquid form is selected from the group consisting of an aqueous solution, an emulsion, a suspension solution, a suspension reconstituted from non-effervescent or effervescent preparations, and a suspension in pharmaceutically acceptable fats or oils.

Please add the following Claims 28-44, as indicated below:

--28. A pharmaceutical composition according to Claim 20 wherein said 2-thienyl imidazolo[4,5]pyridine is in the form of a pharmaceutical addition salt thereof.

29. A pharmaceutical composition according to Claim 28 wherein said pharmaceutical addition salt is a chloride.

30. A pharmaceutical composition according to Claim 20 wherein said 2-thienyl imidazolo[4,5]pyridine is in the form of a prodrug thereof.

31. A pharmaceutical composition according to Claim 20 wherein said 2-thienyl imidazolo[4,5]pyridine is in the form of a liposome delivery system.

32. A pharmaceutical composition comprising a therapeutically effective amount of 2-(2-thienyl)imidazolo[4,5-b]pyridine, having the formula:



33. A pharmaceutical composition according to Claim 32 wherein said 2-(2-thienyl)imidazolo[4,5-b]pyridine is in the form of a pharmaceutical addition salt thereof.

34. A pharmaceutical composition according to Claim 33 wherein said pharmaceutical addition salt is a hydrochloride salt.

35. A pharmaceutical composition according to Claim 32 wherein said 2-(2-thienyl)imidazolo[4,5-b]pyridine is in the form of a prodrug thereof.

36. A pharmaceutical composition according to Claim 32 wherein said 2-(2-thienyl)imidazolo[4,5-b]pyridine is in the form of a liposome delivery system.

37. A pharmaceutical composition according to Claim 32 comprising a pharmaceutical carrier and from about 1 mg to about 600 mg of said 2-(2-thienyl)imidazolo[4,5-b]pyridine.

38. A pharmaceutical composition according to Claim 37 wherein said pharmaceutical carrier is selected from the group consisting of lactose, sucrose, gelatin, cyclodextrin, substituted cyclodextrin, agar, an aqueous solution, an emulsion, a suspension solution, a suspension reconstituted from non-effervescent or effervescent preparations, and a suspension in pharmaceutically acceptable fats or oils.

39. A pharmaceutical composition according to Claim 20 used to treat a viral infection wherein said viral infection is selected from the group consisting of HIV, herpes simplex, hepatitis, and HHV8.

40. A pharmaceutical composition according to Claim 32 used to treat a viral infection wherein said viral infection is selected from the group consisting of HIV, herpes simplex, hepatitis, and HHV8.

41. A pharmaceutical composition according to Claim 20 which further comprises a therapeutic agent.

42. A pharmaceutical composition according to Claim 41 wherein said therapeutic agent is selected from the group consisting of AZT, TC-3, protease inhibitors, acyclovir, famiciclovir, valacyclovir, Ribavirin, interferon, a combination of Ribavirin and interferon, a combination of Ribavirin and beta globulin, a recombinant alpha interferon, and mixtures thereof.

43. A pharmaceutical composition according to Claim 41 used to treat a viral infection wherein said viral infection is selected from the group consisting of HIV, herpes simplex, hepatitis, and HHV8.

44. A pharmaceutical composition according to Claim 43 wherein said viral infection is HIV and said therapeutic agent is selected from the group consisting of AZT, TC-3, and protease inhibitors.--